Background Heart failure (HF) is associated with excessive extracellular matrix (ECM) deposition and abnormal ECM degradation leading to cardiac fibrosis. Connective Tissue Growth Factor (CTGF) modulates ECM production during inflammatory tissue injury, but available data on CTGF gene expression in failing human heart and its response to mechanical unloading are limited. Methods and Results LV tissue from patients undergoing cardiac transplantation for ischemic (ICM; n=20) and dilated (DCM; n=20) cardiomyopathies, and from nonfailing (NF; n=20) donor hearts were examined. Paired samples (n=15) from patients undergoing LV assist device (LVAD) implantation as “bridge to transplant” (34-1145 days) were also analyzed. There was more interstitial fibrosis in both ICM and DCM compared to NF hearts. Hydroxyproline concentration was also significantly increased in DCM relative to NF samples. The expression of CTGF,TGFB1, COL1-A1, COL3-A1, MMP2 and MMP9 mRNAs in ICM and DCM were also significantly elevated as compared to NF controls. Although TGFB1, CTGF, COL1-A1, and COL3-A1 mRNA levels were reduced by unloading, there was only a modest reduction in tissue fibrosis and no difference in protein-bound hydroxyproline concentration between pre- and post-LVAD tissue samples. The persistent fibrosis may be related to a concomitant reduction in MMP9 mRNA and protein levels following unloading. Conclusions CTGF may be a key regulator of fibrosis during maladaptive remodeling and progression to HF. Although mechanical unloading normalizes most genotypic and functional abnormalities, its effect on ECM remodeling during HF is incomplete.
marel. Isoenzyme-selective regulation of SERCA2 gene expression by protein kinase C in neonatal rat ventricular myocytes. Am J Physiol Cell Physiol 285: C39-C47, 2003. First published February 26, 2003 10.1152/ajpcell.00461. 2002-Patients with cardiac hypertrophy and heart failure display abnormally slowed myocardial relaxation, which is associated with downregulation of sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA2) gene expression. We previously showed that SERCA2 downregulation can be simulated in cultured neonatal rat ventricular myocytes (NRVM) by treatment with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA). However, NRVM express three different PMA-sensitive PKC isoenzymes (PKC␣, PKC⑀, and PKC␦), which may be differentially regulated and have specific functions in the cardiomyocyte. Therefore, in this study we used adenoviral vectors encoding wild-type (wt) and kinase-defective, dominant negative (dn) mutant forms of PKC␣, PKC⑀, and PKC␦ to analyze their individual effects in regulating SERCA2 gene expression in NRVM. Overexpression of wtPKC⑀ and wtPKC␦, but not wtPKC␣, was sufficient to downregulate SERCA2 mRNA levels, as assessed by Northern blotting and quantitative, real-time RT-PCR (69 Ϯ 7 and 61 Ϯ 9% of control levels for wtPKC⑀ and wtPKC␦, respectively; P Ͻ 0.05 for each adenovirus; n ϭ 8 experiments). Conversely, overexpression of all three dnPKCs appeared to significantly increase SERCA2 mRNA levels (dnPKC␦ Ͼ dnPKC⑀ Ͼ dnPKC␣). dnPKC␦ overexpression produced the largest increase (2.8 Ϯ 1.0-fold; n ϭ 11 experiments). However, PMA treatment was still sufficient to downregulate SERCA2 mRNA levels despite overexpression of each dominant negative mutant. These data indicate that the novel PKC isoenzymes PKC⑀ and PKC␦ selectively regulate SERCA2 gene expression in cardiomyocytes but that neither PKC alone is necessary for this effect if the other novel PKC can be activated.heart; signal transduction; hypertrophy; transcription; mRNA stability; sarco(endo)plasmic reticulum Ca 2ϩ -ATPase HEART FAILURE (HF) is the final common syndrome of most primary cardiovascular diseases, including coronary atherosclerosis, hypertension, cardiomyopathy, and valvular and congenital heart malformations (17). Despite the varied primary causes of HF, mechanical overload, increased wall stress, and neurohormonal activation are common features that precede the HF state. In response to these mechanical and neurohormonal stimuli, the process of ventricular remodeling is initiated, which is associated with numerous changes in myocardial gene expression and protein turnover. Cultured neonatal rat ventricular myocytes (NRVM) have proven to be useful tools in understanding the cellular mechanisms regulating SERCA2 gene expression in response to neurohormonal and mechanical stimuli. For instance, previous studies have shown that SERCA2 gene expression is regulated by peptide growth factors (33), thyroid hormones (24), angiotensin II (28), endothelin-1 (ET) (23), and norepinephrine (9). Studies fro...
Proline-rich tyrosine kinase 2 (PYK2) is a member of the focal adhesion kinase (FAK) family of nonreceptor protein tyrosine kinases. PYK2 has been implicated in linking G protein-coupled receptors to activation of mitogen-activated protein kinase cascades and cellular growth in a variety of cell types. To determine whether PYK2 expression and phosphorylation is altered in left ventricular (LV) myocardium undergoing LV hypertrophy (LVH) and heart failure in vivo, suprarenal abdominal aortic coarctation was performed in 160-g male Sprague-Dawley rats. Immunohistochemistry and Western blotting were performed on LV tissue 1, 8, and 24 wk after aortic banding. Aortic banding produced sustained hypertension and gradually developing LVH. PYK2 levels were increased 1.8 Ϯ 0.2-, 2.7 Ϯ 0.6-, and 2.0 Ϯ 0.2-fold in 1-, 8-, and 24-wk banded animals compared with their respective sham-operated controls. The increase in PYK2 expression was paralleled by an increase in PYK2 phosphorylation, both of which preceded the development of LVH. Immunohistochemistry revealed that enhanced PYK2 expression occurred predominantly in the cardiomyocyte population. Furthermore, there was a high degree of correlation (R ϭ 0.75; P Ͻ 0.001) between the level of PYK2 and the degree of LVH in 24-wk sham and banded animals. In contrast, FAK levels and FAK phosphorylation were not increased before the development of LVH. However, there was a high degree of correlation (R ϭ 0.68; P Ͻ 0.001) between the level of FAK and the degree of LVH in 24-wk sham and banded rats. There was also a significant increase in the ratio of phosphospecific anti-FAK to FAK at this time point. These data are consistent with a role for PYK2 in the induction of pressure overload-induced cardiomyocyte hypertrophy, and suggest that PYK2 and FAK have distinctly different roles in LVH progression. signal transduction; cytoskeleton; heart failure; focal adhesion kinase CARDIAC HYPERTROPHY is a compensatory process that leads to a heart better suited for the functional demands caused by myocyte dysfunction or loss. Because cardiac myocytes are terminally differentiated and nonproliferative, hypertrophic myocytes demonstrate an increase in protein content rather than an increase in myocyte number. Cardiac hypertrophy is also associated with sarcomeric reorganization and characteristic changes in gene expression and protein turnover. Cardiac hypertrophy, however, may independently lead to cardiac dysfunction and is also a common feature associated with the heart failure state. Despite advancements in the treatment and understanding of the pathogenesis of heart failure, the cellular and molecular mechanisms involved in hypertrophy induction are still largely unknown.Recent studies (12,17,18) have suggested that nonreceptor protein tyrosine kinases are important in transducing mechanical stimuli to biochemical pathways that lead to cardiomyocyte hypertrophy. Prolinerich tyrosine kinase 2 (PYK2) and focal adhesion kinase (FAK) are members of the FAK family of nonreceptor protein tyrosin...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.